General Information of Drug (ID: DMR93WE)

Drug Name
APG-103 Drug Info
Synonyms CD95 receptor inhibitor (inflammatory disease), Apogenix
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Investigative [1]
Cross-matching ID
TTD Drug ID
DMR93WE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VB-111 DMX04CA Malignant glioma 2A00.0 Phase 3 [2]
DE-098 DM5XT3G Rheumatoid arthritis FA20 Phase 2 [3]
APG-101 DM0FXMZ Cerebrovascular ischaemia 8B1Z Phase 2 [4]
APO-010 DMPJBCR Multiple myeloma 2A83 Phase 1 [5]
2-aminophenoxazine-3-one DMBVGAO T-cell leukaemia 2A90 Investigative [6]
F61F12 DMD7HO8 Solid tumour/cancer 2A00-2F9Z Investigative [1]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis mediating surface antigen FAS (FAS) TTF0RCZ TNR6_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
2 Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
3 ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221.
4 Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.
5 APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64.
6 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.